Sai Life Sciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Data Patterns (India) Ltd, K E C International Ltd, Elgi Equipments Ltd, Doms Industries Ltd are among the other stocks to see a surge in volumes on NSE today, 15 April 2025.

Sai Life Sciences Ltd recorded volume of 48.83 lakh shares by 14:14 IST on NSE, a 12.31 times surge over two-week average daily volume of 3.97 lakh shares. The stock gained 13.38% to Rs.759.05. Volumes stood at 1.87 lakh shares in the last session.

Data Patterns (India) Ltd notched up volume of 48 lakh shares by 14:14 IST on NSE, a 10.71 fold spurt over two-week average daily volume of 4.48 lakh shares. The stock rose 12.36% to Rs.1,889.80. Volumes stood at 2.66 lakh shares in the last session.

K E C International Ltd registered volume of 56.9 lakh shares by 14:14 IST on NSE, a 4.47 fold spurt over two-week average daily volume of 12.72 lakh shares. The stock rose 8.39% to Rs.715.45. Volumes stood at 10.04 lakh shares in the last session.

Elgi Equipments Ltd saw volume of 29.6 lakh shares by 14:14 IST on NSE, a 4.43 fold spurt over two-week average daily volume of 6.68 lakh shares. The stock increased 5.55% to Rs.445.60. Volumes stood at 21.07 lakh shares in the last session.

Doms Industries Ltd clocked volume of 4.43 lakh shares by 14:14 IST on NSE, a 4.38 times surge over two-week average daily volume of 1.01 lakh shares. The stock gained 1.61% to Rs.2,641.30. Volumes stood at 97276 shares in the last session.

Powered by Capital Market - Live News

 Sai Life Sciences has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.

Maneesh Pingle, Head of Discovery Services, said: ?The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients' evolving needs as they advance peptide therapies across diverse therapeutic areas.

Powered by Capital Market - Live News

Net profit of Sai Life Sciences rose 35.95% to Rs 53.85 crore in the quarter ended December 2024 as against Rs 39.61 crore during the previous quarter ended December 2023. Sales rose 14.64% to Rs 439.78 crore in the quarter ended December 2024 as against Rs 383.63 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

 Sai Life Sciences has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.

Maneesh Pingle, Head of Discovery Services, said: ?The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients' evolving needs as they advance peptide therapies across diverse therapeutic areas.

Powered by Capital Market - Live News

Net profit of Sai Life Sciences rose 35.95% to Rs 53.85 crore in the quarter ended December 2024 as against Rs 39.61 crore during the previous quarter ended December 2023. Sales rose 14.64% to Rs 439.78 crore in the quarter ended December 2024 as against Rs 383.63 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 6 February 2025.

Powered by Capital Market - Live News

Data Patterns (India) Ltd, K E C International Ltd, Elgi Equipments Ltd, Doms Industries Ltd are among the other stocks to see a surge in volumes on NSE today, 15 April 2025.

Sai Life Sciences Ltd recorded volume of 48.83 lakh shares by 14:14 IST on NSE, a 12.31 times surge over two-week average daily volume of 3.97 lakh shares. The stock gained 13.38% to Rs.759.05. Volumes stood at 1.87 lakh shares in the last session.

Data Patterns (India) Ltd notched up volume of 48 lakh shares by 14:14 IST on NSE, a 10.71 fold spurt over two-week average daily volume of 4.48 lakh shares. The stock rose 12.36% to Rs.1,889.80. Volumes stood at 2.66 lakh shares in the last session.

K E C International Ltd registered volume of 56.9 lakh shares by 14:14 IST on NSE, a 4.47 fold spurt over two-week average daily volume of 12.72 lakh shares. The stock rose 8.39% to Rs.715.45. Volumes stood at 10.04 lakh shares in the last session.

Elgi Equipments Ltd saw volume of 29.6 lakh shares by 14:14 IST on NSE, a 4.43 fold spurt over two-week average daily volume of 6.68 lakh shares. The stock increased 5.55% to Rs.445.60. Volumes stood at 21.07 lakh shares in the last session.

Doms Industries Ltd clocked volume of 4.43 lakh shares by 14:14 IST on NSE, a 4.38 times surge over two-week average daily volume of 1.01 lakh shares. The stock gained 1.61% to Rs.2,641.30. Volumes stood at 97276 shares in the last session.

Powered by Capital Market - Live News

 Sai Life Sciences has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.

Maneesh Pingle, Head of Discovery Services, said: ?The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients' evolving needs as they advance peptide therapies across diverse therapeutic areas.

Powered by Capital Market - Live News

Net profit of Sai Life Sciences rose 35.95% to Rs 53.85 crore in the quarter ended December 2024 as against Rs 39.61 crore during the previous quarter ended December 2023. Sales rose 14.64% to Rs 439.78 crore in the quarter ended December 2024 as against Rs 383.63 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

 Sai Life Sciences has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.

Maneesh Pingle, Head of Discovery Services, said: ?The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients' evolving needs as they advance peptide therapies across diverse therapeutic areas.

Powered by Capital Market - Live News

Net profit of Sai Life Sciences rose 35.95% to Rs 53.85 crore in the quarter ended December 2024 as against Rs 39.61 crore during the previous quarter ended December 2023. Sales rose 14.64% to Rs 439.78 crore in the quarter ended December 2024 as against Rs 383.63 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 6 February 2025.

Powered by Capital Market - Live News